Irene knuesel zurich. Corresponding Author’s address: Dr Irene Knuesel Institute of Pharmacology and Toxicology University of Zurich Winterthurerstrasse 190 CH-8057, Zurich Switzerland Phone: +41 044 635 5997 E-mail: knuesel@pharma. Following her postdoctoral training at Caltech, USA with Mary B. She previously worked at SNSF Swiss National Science Foundation as a Head Division Biology and Medicine. Oct 19, 2022 · Irene Knuesel obtained a PhD in Molecular Neuroscience from the University of Zurich and also a PD from the University of Zurich’s Medical faculty. Irene Knuesel is the Chief Scientific Officer of Rewind Therapeutics. Experience: Rewind Therapeutics · Education: Caltech · Location: Belgium · 500+ connections on LinkedIn. View Irene Knuesel’s profile on LinkedIn, a professional community of 1 billion members. Bringing your innovation to clinical development Irene Knuesel, PhD EDUCATION WORK EXERIENCE OTHER PROFESSIONAL ACTIVITIES External Advisory Board Member: NIH Alzheimer’s Disease Sequencing Program (ADSP) Member of the Society for Neuroscience (SfN) Member of the Swiss Society for Neuroscience SCIENTIFIC CREDENTIALS Irene Knuesel obtained a PhD in Molecular Neuroscience from the University of Zurich and also a PD (Venia Legendi in Neuropharmacology) from the University of Zurich’s Medical faculty. Irene KNUESEL, Chief Scientific Officer | Cited by 6,509 | | Read 96 publications | Contact Irene KNUESEL View the executive profile of Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics, on Equilar ExecAtlas to see current and past work history and gain access to Irene Knuesel's network of 14 business contacts. uzh. „We warmly welcome Irene as our new CSO and are excited that she joins Rewind,“ said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics. ch. "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics. Despite tremendous investments in understanding the complex molecular mechanisms underlying Alzheimer disease (AD), recent clinical trials have failed to show efficacy. “We warmly welcome Irene as our new CSO and are excited that she joins Rewind,” said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics. A potential problem underlying these failures is the assumption that the molecular mechanism mediating the genetically determined f … Oct 19, 2022 · Irene Knuesel obtained a PhD in Molecular Neuroscience from the University of Zurich and also a PD from the University of Zurich’s Medical faculty. in Molecular Neuroscience from the University of Zurich, Switzerland. Irene received her Ph. Kennedy, she was junior group leader and principal investigator at the Technical University of Zurich (ETH) and University of Zurich, respectively. Irene Knuesel attended the University of Zurich. D. r30s isdk d6 1ro exkz5 sg j5ho8oy pmzr wac 50kk